Abstract:Arteriovenous fistulas (AVFs) are the most common access created for hemodialysis, but up to 40% fail to mature, suggesting a need to improve AVF maturation. In a mouse model, reduced Akt1 expression reduces fistula wall thickness and diameter while improving patency. We hypothesized that inhibition of the Akt1-mechanistic target of rapamycin complex 1 (mTORC1) axis alters venous remodeling associated with failure of AVF maturation. A C57BL6/J mouse aortocaval fistula model was used (male, 9-12 weeks). Mice were injected with 100 μg of vehicle or rapamycin (intraperitoneal) daily. The AVFs (venous limb) were harvested at days 3, 7, and 21 for analysis. AVF patency and diameter were assessed with ultrasound measurements. AVFs were compared for wall thickness, M1 and M2 macrophage markers, and expression level of mTOR signaling proteins using Western blot and immunofluorescence intensity. Rapamycin reduced AVF wall thickness at days 7 and 21 (P < .0001; n = 5-9) without any change in AVF diameter (P = .534; n = 6). Rapamycin decreased proliferating cell nuclear antigen immunoreactivity in smooth muscle cells (SMCs) and macrophages (P < .0001; n = 4-5). Rapamycin also reduced both M1 (inducible nitric oxide synthase, tumor necrosis factor α) and M2 (interleukin 10 and CD206) macrophage protein expression (days 3 and 7, P < .05; n = 2) and immunoreactivity in AVFs at days 3 and 7 (P < .05; n = 4-5). Rapamycin treatment was associated with diminished phosphorylation of the mTORC1 pathway, with less phosphorylation of mTOR (Ser2481), Akt1, 4EBP1, and p70S6K (P < .001; n = 6) but not of the mTORC2 pathway members mTOR (Ser2448), protein kinase C α, and SGK1 (P > .4; n = 6). Mice treated with rapamycin showed decreased co-localization of p-Akt1/α-actin and p-mTORC1/α-actin immunoreactivity at days 7 and 21 (P < .05; n = 4-5). Similarly, mice treated with rapamycin had decreased co-localization of p-Akt1/CD68 and p-mTORC1/CD68 immunoreactivity at days 3, 7, and 21 (P < .05; n = 4-5). Macrophage depletion with clodronate liposomes reduced AVF wall thickness compared with control veins (P < .01, day 21; n = 5). Macrophage depletion also reduced SMC proliferation (P = .0035; n = 4-5) and p-mTORC1 immunoreactivity in SMCs (P = .0011; n = 4-5). Rapamycin improved AVF patency by day 42 (P = .0495; n = 13-14). These AVFs showed persistently less thickening (P < .0001; n = 5) but similar rate of dilation compared with control AVFs (P = .2603; n = 6-7). Interestingly, at day 42, AVFs in rapamycin-treated mice had similar co-localized p-Akt1/CD68 and p-mTORC1/CD68 (P > .52; n = 5) immunoreactivity compared with control AVFs. Rapamycin improves AVF patency by reducing early inflammation and wall thickening through the Akt1-mTORC1 signaling pathway in macrophages and SMCs. Rapamycin may be a translational strategy to improve AVF patency.

Rapamicina Em Combinação Com A-Cianoacrilato Contribui À Inibição De Hiperplasia Intimal Em Modelos Em Ratos

Local Applied Slow-Releasing Rapamycin Inhibits Neointima Hyperplasia in Vein Graft

Influence of atorvastatin on ion pump activity of smooth muscle cells and intima proliferation after arterial intimal injury

A Adiponectina Previne a Reestenose Pela Inibição Da Proliferação Celular Em Um Modelo De Enxerto Venoso Em Ratos

Effect of Rapamycin on Phenotype of Vascular Smooth Muscle Cell and Arterial Intimal Hyperplasia in Rat Cardiac Allograft

[Pretreatment of Isolated Vein with Rapamycin Nanoparticles Inhibits Vein Graft Stenosis in Rabbits].

Pretreatment with Intraluminal Rapamycin Nanoparticle Perfusion Inhibits Neointimal Hyperplasia in a Rabbit Vein Graft Model

Atorvastatin Reduces Accumulation of Vascular Smooth Muscle Cells to Inhibit Intimal Hyperplasia Via P38 MAPK Pathway Inhibition in a Rat Model of Vein Graft.

Adiponectin Prevents Restenosis Through Inhibiting Cell Proliferation in a Rat Vein Graft Model

The Relationship Between Local Renin-Angiotensin System and Intimal Proliferation in an Organ Culture of Human Saphenous Veins

P38 MAPK Inhibitor, CBS3830 Limits Vascular Remodelling in Arterialised Vein Grafts.

Inhibition of Neointima Hyperplasia of Mouse Vein Grafts by Locally Applied Suramin

Effects of SDF-1α on vein graft restenosis in rats

PC220. Rapamycin Alters Venous Remodeling to Improve Arteriovenous Fistula Patency

MicroRNA-146a sponge therapy suppresses neointimal formation in rat vein grafts.

The Selective RNA Polymerase I Inhibitor CX-5461 Mitigates Neointimal Remodeling in a Modified Model of Rat Aortic Transplantation

Inhibitory effect of Psilencer1.0-U6-siRNA-stat3 on neointima hyperplasia of vein graft after arterial bypass

Effect and mechanism of p38MAPK inhibitor CBS3830 on intimal hyperplasia in autogenous vein grafts of diabetic rats

Rapamycin to Prevent Artery Restenosis after Stent Implantation:An Intravascular Ultrasound Study

All-trans-retinoic Acid Decreases Smooth Muscle Cell Proliferation and Increases Apoptosis in an Animal Model of Vein Bypass Grafting

The Experimental Study on the Effects of Rapamycin and Statin on Chronic Transplant Vasculopathy